Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Metabolic brain disease

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1023271908568PMID 9804365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study.

  1996cited by this paper
• Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study.

  1995cited by this paper
• Flumazenil in cirrhotic patients in hepatic coma: A randomized double‐blind placebo‐controlled crossover trial

  1994cited by this paper
• Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy

  1994influential reference
• Elevated Brain Concentrations of 1, 4-Benzodiazepines in Fulminant Hepatic Failure

  1992cited by this paper
• Persisting benzodiazepine metabolites responsible for the reaction to the benzodiazepine antagonist flumazenil in patients with hepatic encephalopathy.

  1991cited by this paper
• Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

  1991cited by this paper
• The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands.

  1991cited by this paper
• Endogenous Benzodiazepine Receptor Ligands in Human and Animal Hepatic Encephalopathy

  1990cited by this paper
• Effects of the Benzodiazepine Receptor Antagonist Flumazenil in Hepatic Encephalopathy in Humans

  1990cited by this paper
• [Benzodiazepines and liver diseases. Pharmacokinetics and pharmacodynamic effects].

  1990cited by this paper
• "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy.

  1990cited by this paper
• Flumazenil and hepatic encephalopathy.

  1989cited by this paper
• Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans.

  1989cited by this paper
• Pharmacokinetics of benzodiazepine antagonist Ro 15–1788 in cirrhotic patients with moderate or severe liver dysfunction

  1989cited by this paper
• GABAA Receptor Complex in an Experimental Model of Hepatic Encephalopathy: Evidence for Elevated Levels of an Endogenous Benzodiazepine Receptor Ligand

  1989cited by this paper
• Improvement of hepatic encephalopathy treated with flumazenil.

  1988cited by this paper
• IMPROVEMENT OF HEPATIC ENCEPHALOPATHY TREATED WITH FLUMAZENIL

  1988cited by this paper
• Affinities and densities of high‐affinity [3H]muscimol (GABA‐A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy

  1988cited by this paper
• Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure.

  1987cited by this paper
• Pathogenesis of hepatic encephalopathy

  1987cited by this paper
• Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy.

  1987cited by this paper
• Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788)

  1985cited by this paper
• Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist.

  1984cited by this paper
• Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure.

  1983cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations

  2019cites this paper
• MetaboRank: network-based recommendation system to interpret and enrich metabolomics results

  2018cites this paper
• Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites

  2018cites this paper
• GABAergic transmission in hepatic encephalopathy.

  2013cites this paper
• [Alcohol dependence: diagnosis and treatment].

  2008cites this paper
• Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma.

  2006cites this paper
• Role of Endogenous Benzodiazepine Ligands and Their GABA-A-Associated Receptors in Hepatic Encephalopathy

  2005cites this paper
• Pathophysiology of Hepatic Encephalopathy: A New Look at GABA from the Molecular Standpoint

  2004cites this paper
• Increased Brain Concentrations of Endogenous (Non-benzodiazepine) GABA-A Receptor Ligands in Human Hepatic Encephalopathy

  2004cites this paper
• Normal coupling of brain benzodiazepine and neurosteroid modulatory sites on the GABA-A receptor complex in human hepatic encephalopathy.

  2003cites this paper
• Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices

  2003cites this paper
• Neurobiology of ammonia.

  2002cites this paper
• Concomitant overdosing of other drugs in patients with paracetamol poisoning.

  2002cites this paper